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Background: Recently, inflammatory cascades have been suggested as a target for epilepsy therapy. Positron
emission tomography (PET) imaging offers the unique possibility to evaluate brain inflammation longitudinally in a
non-invasive translational manner. This study investigated brain inflammation during early epileptogenesis in
the post-kainic acid-induced status epilepticus (KASE) model with post-mortem histology and in vivo with
[18F]-PBR111 PET.
Methods: Status epilepticus (SE) was induced (N = 13) by low-dose injections of KA, while controls (N = 9) received
saline. Translocator protein (TSPO) expression and microglia activation were assessed with [125I]-CLINDE
autoradiography and OX-42 immunohistochemistry, respectively, 7 days post-SE. In a subgroup of rats, [18F]-PBR111
PET imaging with metabolite-corrected input function was performed before post-mortem evaluation. [18F]-PBR111
volume of distribution (Vt) in volume of interests (VOIs) was quantified by means of kinetic modelling and a
VOI/metabolite-corrected plasma activity ratio.
Results: Animals with substantial SE showed huge overexpression of TSPO in vitro in relevant brain regions such as
the hippocampus and amygdala (P < 0.001), while animals with mild symptoms displayed a smaller increase in
TSPO in amygdala only (P < 0.001). TSPO expression was associated with OX-42 signal but without obvious cell loss.
Similar in vivo [18F]-PBR111 increases in Vt and the simplified ratio were found in key regions such as the
hippocampus (P < 0.05) and amygdala (P < 0.01).
Conclusion: Both post-mortem and in vivo methods substantiate that the brain regions important in seizure
generation display significant brain inflammation during epileptogenesis in the KASE model. This work enables
future longitudinal investigation of the role of brain inflammation during epileptogenesis and evaluation of
anti-inflammatory treatments.
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Various brain injuries in humans such as neurotrauma,
stroke, infection, febrile convulsions and status epilepticus
(SE) are associated with the acute occurrence of seizures
and an increased risk of developing epilepsy. The neurobio-
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reproduction in any medium, provided the origare still incompletely understood. An important feature
regulating the reorganisation of the neuronal network after
the occurrence of a neuronal insult is brain inflammation.
In recent years, evidence from animal and clinical studies
has been accumulating which supports the hypothesis that
inflammatory processes within the brain might constitute a
common and crucial mechanism in the pathophysiology of
seizures and epilepsy [1,2]. This has raised interest in inves-
tigating the potential of anti-inflammatory treatment strat-
egies for epilepsy [2,3]. However, to efficiently target brain
inflammation, we need to increase our understanding of itsr. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Table 1 Overview of the number of animals and
procedures used in each experiment
[18F]-PBR111
metabolism
post-mortem
evaluationa (in vitro
[18F]-PBR111b)
Ex vivo
[18F]-PBR111c
In vivo
[18F]-PBR111
PET and
post-mortem
evaluationd
Control (n) 4 (1) 1 4
Minor SE (n) 3 (0) 0 0
Medium SE (n) 3 (1) 1 2
Severe SE (n) 0 (0) 1 3
aPost-mortem evaluation was performed on sagittal sections and included
in vitro [125I]-CLINDE autoradiography and OX-42 immunohistochemistry for all
animals; bin vitro [18F]-PBR111 in two representative animals; cex vivo [18F]-
PBR111 binding was measured in sagittal sections; dpost-mortem evaluation
was performed on coronal sections in these animals and included in vitro
[125I]-CLINDE autoradiography, OX-42 immunohistochemistry and Cresyl Echt
Violet staining.
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pro-epileptic as well as homeostatic protective mechanisms
[1-3].
Epileptogenesis is difficult to study in human patients
in a systematic, unbiased prospective manner. Also, the
tissue is only available from the very small percentage of
temporal lobe epilepsy (TLE) patients that undergo
epilepsy surgery. TLE is the most common and severe
form of focal epilepsy in adults and is often unsatisfac-
torily controlled with medical therapy. Animal models
offer a distinct advantage to study TLE by allowing the
assessment of baseline, developing and chronic epileptic
states. Nevertheless, traditional neuroscientific techniques
(e.g. histology) can only examine the brain at one time
point during the epileptogenic processes in any individual
animal. The recent advances in dedicated imaging techni-
ques such as small animal positron emission tomography
(PET) allow, for the first time, researchers to study in vivo
changes during the process of epileptogenesis as well as
treatment response by means of serial acquisitions in the
same animal [4]. Several groups have recently developed
radioligands, which are translocator protein (TSPO) spe-
cific and potentially very interesting for clinical use. TSPO
or previously named peripheral benzodiazepine receptor
(PBR), which is a marker of activated glia, has been
detected in surgically resected brain tissue and most re-
cently in vivo with PET in patients with TLE [5-8]. Such
biomarkers may become of particular value to aide in
patient diagnoses and/or stratification, to evaluate the
effect of new drug therapies on brain inflammation and
for resective surgery of the epileptogenic zone [6,8].
[18F]-PBR111, with high specificity for the TSPO receptor,
has suitable in vivo characteristics to be used as a brain
inflammation imaging biomarker [9,10]. The aim of this
comprehensive study was to investigate brain inflamma-
tion during early epileptogenesis in the post-kainic acid-
induced SE (KASE) model for TLE with post-mortem
histology and in vivo [18F]-PBR111 small animal PET.
Methods
Animals
All experiments were approved by the Institutional Animal
Care and Ethics Committee at the Australian Nuclear
Science and Technology Organisation (NSW, Australia)
and were in strict accordance with the Australian Code
of Practice for the Care and Use of Animals for Scientific
Purposes.
Adult male Wistar rats (7-week-old) were purchased
from the Australian Resources Centre (Canning Vale,
Australia) and used for metabolite, ex vivo or PET imaging
studies. They were acclimatised for 1 week and subse-
quently single-housed under a 12-h light/dark cycle, in a
temperature and humidity controlled environment, with
food and water available ad libitum. All efforts were madeto minimise pain or discomfort to the animals during
experimental procedures.
SE was induced in 13 male Wistar rats (286 ± 4 g) as
described before [11,12]. Briefly, by step-wise intraperi-
toneal (i.p.) injections of kainic acid (A.G. Scientific, San
Diego, CA, USA) (2.5 to 5 mg/kg, total dose 7.5 to
22.5 mg/kg, mean total dose 12.7 ± 1.4 mg/kg), sus-
tained seizure activity was induced for 4 h, while control
rats (280 ± 9 g, N = 9) received saline injections
(Table 1). Where seizures during SE were too violent
and life-threatening, a half dose of diazepam (2 mg/kg)
was given during SE. Following 4 h of SE, animals
were given diazepam (4 mg/kg, i.p.) to terminate SE.
Animals were classified into three groups regarding the
severity of the SE employing the scale of Racine [13]:
firstly, minor SE was defined as predominantly non-
convulsive seizure activity (class I to II seizures) with
some forelimb cloni (class III); secondly, medium SE
includes all seizure classes up to some occasional class
IV seizures (rearing with falling) and continuous auto-
matisms (head nodding, erect tail, hyperactivity, etc.);
and thirdly, severe SE includes all seizure classes up to
several class V seizures (rearing with falling), tonic clonic
convulsions, bouncing and continuous automatisms. Ani-
mals were used for metabolite, ex vivo and PET imaging
studies (Table 1) 7 days post-induction, as previous studies
have shown significant brain inflammation/TSPO upre-
gulation in this model during this period [14-16].Radiosynthesis of [125I]-CLINDE
The radiotracer [125I]-CLINDE was synthesised as previ-
ously described [17,18] in 65% to 80% radiochemical
yield and >97% radiochemical purity. For autoradiog-
raphy, unlabelled CLINDE was added to [125I]-CLINDE
to achieve a specific activity of 3.7 GBq/μmol.
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[18F]-PBR111 was prepared using automated methods
on the GE Tracerlab FXFN (GE Healthcare, Milwaukee,
WI, USA) as previously published [19]. Briefly, 2 mg of
the p-toluenesulfonyl precursor of PBR111, dissolved
in anhydrous acetonitrile, was added to pre-dried K
[18F]-K2.2.2·K2CO3 complex, prepared from an aqueous
[18F]-fluoride solution (37 to 150 GBq). The reaction
was heated at 100°C for 5 min before the reaction
mixture was diluted with mobile phase and purified by
preparative reverse phase chromatography. The collected
radioactive peak was concentrated using a C18-solid phase
extraction cartridge with subsequent formulation to a con-
centration of 20 MBq/100 μL of saline containing less than
1% ethanol for the biological studies. [18F]-PBR111 was
produced in 25% to 35% radiochemical yield (non-decay
corrected) with radiochemical purity exceeding 97% and
specific activity of 215 ± 46 GBq/μmol.
Metabolite studies
To establish a standard curve of [18F]-PBR111 metabol-
ism, blood samples were obtained in four control rats
(304 ± 10 g) and six KASE rats (312 ± 8 g, minor to
medium SE), which were maintained under anaesthesia
to mimic the conditions of the PET scan (Table 1). Ani-
mals were anaesthetised with 5% isoflurane for induction
and 1% to 3% for maintenance, administered in medical
oxygen. An incision was made in the inner thigh of the
hind leg, and the femoral artery was exposed and loosely
tied off after blunt dissection of the surrounding tissue.
A polyethylene cannula filled with heparinised saline
(20 IU/ml) was placed into the femoral artery and threaded
3 cm proximally.
Animals were injected intravenously with [18F]-
PBR111 (injected dose (ID) = 14.1 to 38.7 MBq). The
tracer was infused via the dorsal penile vein (maximum
volume of 0.3 ml) using a Harvard Apparatus Pump 11
plus syringe pump (Holliston, MA, USA) over a constant
time interval of 1 min. The line was flushed with saline,
and the remaining radioactivity was measured in the line
and syringe. Different ranges of tracer mass (0.07 to
4.00 nmol) were injected to evaluate whether this would
affect the tracer metabolism. Arterial blood samples
(0.2 ml) were withdrawn via a cannula implanted in
the femoral artery from 2 to 60 min after the start of
injection. The whole blood was then centrifuged at
3,000 rpm for 10 min, and the plasma was collected.
Plasma samples (0.1 ml) were weighed and the radio-
activity was measured in a Wallac γ-counter. At 2- and
5-min post-injections, the samples were taken in dupli-
cate. One sample was left on the bench for 1 h, and the
other was processed immediately to evaluate the stability
in whole rat blood. This showed that [18F]-PBR111 was
not further metabolised in vitro in whole rat blood.Upon termination of blood sampling, the cannula was
removed, the artery was tied off and the skin incision was
sutured. Animals were given buprenorphine (0.05 mg/kg)
as a post-surgical analgesic and killed the following
day by carbon dioxide overdose. The brains were im-
mediately removed and snap frozen for post-mortem
evaluation of brain inflammation.
The metabolite analysis was performed using solid
phase extraction (SPE) that proved to be a sensitive
technique as previously described by [20] to measure
the concentration of unchanged [18F]-PBR111 in rat
plasma [20]. SPE analysis was performed on Oasis car-
tridges (Waters OasisW HLB, 30 μm, 60 mg) that were
preconditioned with 1 ml ethanol followed by 5 ml
water. Rat plasma (100 μl) was mixed with 1 ml
of water containing the unlabelled PBR compound
(10 nmol in 10 μl CH3OH) and KF (200 nmol) and
loaded onto the cartridge. Sequentially, the cartridge
was washed with 1 ml water, 1 ml acetonitrile/water
(20/80, v/v) and 2 ml acetonitrile. All fractions were col-
lected into separate counting tubes. The radioactivity in
each fraction and that remaining on the cartridge was
measured with a Wallac γ-counter. Data were expressed
as the percentage of unmetabolised parent compound
([18F]-PBR111) in the plasma sample.
Post-mortem evaluation of brain inflammation
Frozen brains from animals studied in the metabolism
experiments were used to explore for brain inflammation
and TSPO expression. They were cut (sagittal sections
20 μm and 0.9 and 4.3 mm from bregma according to
the Paxinos and Watson rat atlas [21]) using a cryostat,
thaw-mounted onto the PolysineW microscope slides
(LabServ, Australia), and stored at −80°C.
Immunohistochemistry
On the slide, sections were post-fixed in 10% buffered
formalin (Sigma-Aldrich, St. Louis, MO, USA) for
20 min, washed in 0.1 M phosphate buffered saline
(PBS, 6 × 5 min) and the endogenous peroxidases were
quenched in 3% hydrogen peroxide solution (in 0.1 M
PBS) for 5 min. They were blocked in 3% normal horse
serum (in PBS) for 10 min then incubated overnight in
mouse anti-CD11b (OX-42, Serotec (Kidlington, Ox-
ford, UK), 1:1,000) in antibody diluent (0.1% bovine
serum albumin, 0.2% triton X-100, 2% normal horse
serum in 0.1 M PBS). They were washed in PBS
(2 × 10 min) then incubated with the secondary anti-
bodies (goat biotinylated anti-mouse IgG, Vector Labo-
ratories (Burlingame, CA, USA), 1:500 in antibody
diluent) for 1 h. They were washed in 0.1 M PBS (2 ×
15 min) and incubated in 1:1,000 ExtrAvidin peroxid-
ase (Sigma-Aldrich) in antibody diluent. Labelling was
visualised using a nickel-intensified diaminobenzidine
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0.004% ammonium chloride, 0.2% D-glucose, 0.02%
nickel ammonium sulphate, 0.1% glucose oxidase in 0.1
M phosphate buffer), as previously described in [22].
Slides were air-dried, dehydrated through graded etha-
nol solutions (70%, 95% and 100%), incubated in xylene
and coverslipped using Eukit (Proscitech, Queensland,
Australia) permanent mounting media. Sections incu-
bated without primary antibodies served as negative
controls.
Images were captured using a Q-Imaging Micropubl-
isher 3.3 digital camera (Q-Imaging, Surrey, Canada)
on an Olympus BX41 microscope (Olympus America
Inc., Melville, NY, USA) with epifluorescence and Image-
Pro software (Media Cybernetics, Silver Spring, MD,
USA). Light microscopy images were captured using ×2
and ×10 objectives. Image montages were created from
images captured using a ×2 objective and were non-
destructively positioned using Photoshop CS4 extended
(Adobe, USA). Qualitative analysis of OX-42-labelled
brain sections involved blinded visual inspection for OX-
42 increased signal in the different brain regions in KASE
compared to control groups.In vitro [125I]-CLINDE and [18F]-PBR111 binding
TSPO binding density was assessed using the selective
TSPO ligands, [125I]-CLINDE and [18 F]-PBR111 as
described previously [9,23]. Briefly, adjacent sets of unfixed
sagittal sections were incubated in triplicate with 3 nM
[125I]-CLINDE or 4 nM [18F]-PBR111 in 50 mM Tris buffer
(pH 7.4 at 4°C) for 1 h. Non-specific binding was
assessed with co-incubation with 10 μM PK11195
(Sigma-Aldrich). Sections were washed in ice cold Tris
buffer (2 × 2 min), then distilled water (1 min), before
being air dried on a slide warmer at 37°C. They were
exposed to film, with [14C] polymer standards (ARC,
USA) for calibration of optical density to becquerel
per milligram activity. Films were scanned using a
BioRad GS-800 calibrated densitometer (Bio-Rad La-
boratories, Hercules, CA, USA), and exposure times
were chosen such that the optical density range of the
sections was within the pseudolinear response range of
the film.
Autoradiographic images were calibrated (cubic fit be-
tween optical density and [14C]-standard values) and
quantified using ImageJ (http://rsbweb.nih.gov/ij/). After
visual inspection of the autoradiographic films, regions
with high TSPO binding namely the hippocampus, thal-
amus and amygdala were chosen for quantification, as
well as a region with limited binding namely the inferior
colliculus. Regions of interest were drawn blinded for
control and KASE groups, converted to kilobecquerel
per milligram and specific binding calculated.Ex vivo binding
To evaluate [18F]-PBR111 for in vivo TSPO binding, the
following ex vivo autoradiography study was performed
(Table 1). One control animal (275 g) and two kainic
acid-treated animals (medium and severe SE, 263 to
296 g) were injected i.v. with 37 MBq [18F]-PBR111
under isoflurane anaesthesia (5% induction, 1% to 3%
maintenance in medical oxygen). Thirty minutes later,
the animals were killed with carbon dioxide; the brains
were extracted and snap frozen. The brain sections
were exposed on phosphor imaging plates (SR 2025,
FujiFilm, Japan) overnight. Phosphor imaging plates
were scanned using a BAS-5000 Bioimaging Analyser
(Fujifilm, Japan) to digitise the autoradiograms for
presentation.
[18F]-PBR111 PET imaging of subsequent brain
inflammation and post-mortem validation
Four control (317 ± 8 g) and five KASE (290 ± 8 g) animals
were imaged in vivo with [18F]-PBR111 PET (Table 1).
The KASE group displayed medium to severe SE during
induction.
[18F]-PBR111 PET imaging
Seven days post-SE, rats were anaesthetised for PET im-
aging using isoflurane (induction 5%, maintenance 1% to
3%, in medical oxygen), and body temperature was main-
tained using a feedback-regulated heating pad. A catheter
was implanted in the femoral artery as described above.
The animal was then placed into the field-of-view of the
INVEON PET/CT scanner (Siemens Medical Solutions,
Knoxville, TN, USA) [24], and physiological parameters
(heart rate, respiration and body temperature) were mon-
itored (BioVet, m2m Imaging Corp., Cleveland, OH,
USA) for the entire scanning period. To avoid movement
and fix tubing, the animal was restrained in the supine
position using a webbed sock and adhesive tape.
The PET scan was started 20 to 30 s before the 1-min
infusion of radiotracer (ID = 12.5 to 29.0 MBq, 0.05 to
0.29 nmol, max 0.4 ml in volume, as described above) for
the duration of 60 min. Femoral arterial blood samples
(approximately 50 μl/sample) were taken at 15-s intervals
for 4 min after the commencement of the PET scan, and
then at 10-, 20-, 30- and 50-min post-injections. In the
last sample (100 μl), metabolites were analysed to con-
firm the standard metabolite correction and to calculate
the partition coefficient at 50 min. Heparinised saline
(20 IU) was administered after blood sampling to
maintain the blood volume and to prevent hypotension.
Plasma samples were collected after 10-min centrifuga-
tion of whole blood at 3,000 rpm. Whole blood and
plasma samples were counted in a Wallac γ-counter,
decay-corrected and weight-normalised. At the end of
the PET scanning, a 10-min 70 kV/500 μA computed
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(for co-registration with PET data and magnetic reson-
ance imaging (MRI) atlas).
In a subset of animals (one control and three KA-
treated animals), Evans Blue (EB, 2%, 4 ml/kg) was
injected through the femoral artery catheter under iso-
flurane anaesthesia to assess the integrity of the blood
brain barrier macroscopically [25,26]. Animals were then
sacrificed at the end of the scan using carbon dioxide
overdose. The brains were immediately removed and
frozen in liquid nitrogen and stored at −80°C.
PET image analysis
Coincidence events were acquired into list mode files
and then histogrammed into 31 consecutive frames of
variable duration (8 × 15 s, 6 × 20 s, 6 × 60 s, 3 × 180 s,
and 5 × 500 s). The volumes were then reconstructed
with an iterative algorithm 3D-OSEM/FastMap. PET
images (128 × 128 × 159) were co-registered with CT
scans and mapped to a MRI-based rat brain atlas [27].
Left and right time activity curves (TACs) were derived
from eight VOIs such as the frontal cortex, striatum,
parietal cortex, hippocampus, thalamus, amygdala, oc-
cipital cortex and colliculi using the Anatomist package
(http://brainvisa.info). Also, the hypothalamus, brain-
stem, pons and cerebellum were extracted from the
reconstructed images. Data were then converted into ac-
tivity concentration (kBq/ml) using cross calibration
factors.
Firstly, a two-compartment model was used to assess
the ‘apparent’ volume of distribution (Vt), or the ‘volume’
of the tracer would occupy if the tracers were to adopt
the same concentration in the tissue as in the blood. For
each VOI, Vt was calculated using their TACs, the
metabolite-corrected plasma curve as input function and
the whole blood curve to model the kinetics of the vas-
cular fraction (5%) in the cerebral tissue.
Secondly, the ratio between the VOI activity and the
metabolite-corrected plasma activity (r500) was calcu-
lated to determine its appropriateness for longitudinal
studies without the need of a plasma input function. At
a late time point, r500 was calculated as the ratio of the
activity in the hippocampus, thalamus and amygdala
(frame 49 to 54 min) over the metabolite-corrected
plasma activity at 50 min. Metabolite correction derived
from the standard curve was indicated as r500(SC), while
metabolite correction derived from the blood sample
was indicated as r500.
Post-mortem verification of altered TSPO density, microglial
activation and cell loss
Coronal brain sections (20 μm, −3.24 mm from bregma
according to [21]) were cut using a cryostat, thaw-
mounted onto PolysineW microscope slides (LabServ,Australia), and stored at −80°C. During cutting, pictures
were taken in EB-injected animals to evaluate extravasa-
tion macroscopically. Adjacent sets of unfixed rat brain
sections were analysed in triplicate for quantitative auto-
radiography for TSPO with [125I]-CLINDE, OX-42
(microglial activation) immunohistochemistry and cresyl
violet (cell loss).
Methodology regarding immunohistochemistry was
performed as above. Semi-quantitative analysis included
visual scoring of OX-42 signal as follows: mild (+), mod-
erate (++) and intense (+++) OX-42 signals. For auto-
radiography, a preincubation step of 15 min in Tris
buffer (50 mM, pH 7.4) was added to remove exogenous
TSPO ligand. TSPO binding was assessed as described
above in the cortex, corpus callosum, hippocampus and
hippocampal subregions (CA1, CA2 and CA3/hilus),
thalamus, hypothalamus, amygdala and piriform cortex.
Histological verification of cell loss in hippocampal
pyramidal cell layers (CA1, CA2, CA3 and hilus) was
performed on Nissl-stained sections (using Cresyl Echt
Violet) [21] blinded for the treatment group.Statistical analysis
Statistical analysis was performed with Prism v5.0d for
Mac (GraphPad Software Inc., La Jolla, CA, USA). Bio-
logical half-life of the radiotracer was calculated using
non-linear fitting with a two-phase decay, and compari-
son of fits was performed. TSPO binding between the
control, minor SE and medium SE groups was compared
using one-way ANOVA with Tukey post hoc tests for the
different brain regions. For the PET studies, Vt and post-
mortem TSPO binding between the control and KASE
groups were compared using a Student's t test with
Welch correction if variance was unequal. A value of P <
0.05 was considered significant; a trend was indicated
with P < 0.1. Correlations between Vt, r500 and autoradi-
ography were obtained with Pearson r test. The percent-
age of difference in the KA group was calculated as
(KA − control) / control × 100. Data are expressed as
mean ± standard error of the mean (SEM).Results
Standard metabolite correction
Metabolism of the parent [18F]-PBR111 compound
varied little among the different animals and was not
depending on the injected tracer mass. Although there
was a small difference between the control and KASE
animals in the percentage of parent compound over time
in the plasma, these radioligand metabolism curves were
not significantly different (Figure 1). Data were fitted
with a two-exponential fit (R2 > 0.95), and the biological
short and long half-lifes were in agreement with Katsifis
et al. [20].
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Figure 1 Metabolism of [18F]-PBR111. In the plasma of control
(N = 4) and KASE (N = 6) rats, metabolism of [18F]-PBR111 was
expressed as the percentage of parent compound.
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After injection of KA, animals displayed different levels
of severity of SE during the 4-h induction period. The
severity of the SE correlated with the in vitro TSPO
radioligand [125I]-CLINDE binding. Animals that
experienced medium severity of SE showed significant
increases in TSPO binding in the hippocampus (P < 0.01),
amygdala (P < 0.001) and thalamus (P < 0.01) (Figure 2).
The minor SE group displayed significantly increased
TSPO binding in the amygdala only (P < 0.001) and to a
much lower degree than the medium SE group (Figure 2).
The inferior colliculus, a region not directly involved in
seizure generation was not affected (Figure 2).
In vitro [125I]-CLINDE binding corresponded closely
with OX-42 immunohistochemistry: brain regions in-
cluding the hippocampus, amygdala, thalamus and
piriform cortex were labelled with both methods in
KASE animals (Figure 3). In both control and KASE
animals, ependymal cells of the ventricles and theS
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Figure 2 TSPO binding 7 days post-KASE was depending on the seve
and is expressed as specific binding of [125I]-CLINDE (kBq/mg). HC, hippoca
expressed as mean ± SEM; P < 0.01 (double asterisk) and P < 0.001 (triple aolfactory bulb showed TSPO expression (Figure 3).
The same brain regions were labelled after in vitro
and ex vivo [18F]-PBR111 autoradiography compared
with in vitro [125I]-CLINDE autoradiography
(Figure 3).[18F]-PBR111 PET imaging with post-mortem validation
KASE animals, used for the PET imaging study, displayed
medium to severe SE during induction. Input functions
were corrected using the above-derived standard metab-
olite correction curves fitted with two-exponential fit. As
in the previous experiment, only the control, minor and
medium SE animals were investigated; we also compared
the metabolism between the control and severe SE ani-
mals. The percentage of parent compound at 50-min
post-injection was not significantly different between the
control (20.8 ± 1.3%) and severe SE (20.1 ± 1.3%) ani-
mals. Representative TACs for plasma and a subset of
brain regions are presented in Figure 4, and mean Vt
values for all regions are listed in Table 1. Vt did not dif-
fer significantly between the left and right hemispheres
in the control and KASE-treated rats. In one KASE ani-
mal, Vt was not elevated, and this animal was omitted
from the comparison between the control and KASE
groups. Significant bilateral brain increases of Vt were
found in the left and right striatum (180% and 156%, re-
spectively, P < 0.05), right parietal cortex (136%, P < 0.05),
left and right hippocampus (154%, P < 0.01 and 159%,
P < 0.05, respectively), right thalamus (155%, P < 0.05),
left and right amygdala (288%, P < 0.01 and 284%, P < 0.05,
respectively) and right occipital cortex (62%, P < 0.05)
(Table 1). A trend for a significant difference (P < 0.1) was
found in the left and right frontal cortices (108% and 98%,
respectively), left parietal cortex (110%), left thalamus
(173%) and hypothalamus (104%). In the following
regions, no significant changes were observed after KAIC
TH
AL
Control (n=4)
KASE (minor SE) (n=3)
KASE (medium SE) (n=3)
**
rity of SE. In vitro TSPO binding was performed on sagittal sections
mpus; AMYG, amygdala; IC, inferior colliculus; THAL, thalamus. Data are
sterisk).
Figure 3 Brain inflammation assessed by immunohistochemistry. In vitro and ex vivo TSPO autoradiography on sagittal sections in
representative control and KASE (medium SE) animals demonstrating higher signal in the hippocampus, piriform cortex, amygdala and thalamic
nuclei post-KASE. IHC, immunohistochemistry; ARG, autoradiography, HC, hippocampus; AMYG, amygdala; PIR, piriform cortex; IC, inferior
colliculus; THAL, thalamus.
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http://www.ejnmmires.com/content/2/1/60treatment: the left occipital cortex, colliculi, brainstem,
pons and cerebellum.
Increased [18F]-PBR111 binding was measured in vivo
with PET which corresponds with the brain regions with
increased brain inflammation identified with [125I]-
CLINDE autoradiography and OX-42 immunohisto-
chemistry (Figure 5). Increased [125I]-CLINDE binding
was also observed in the KASE animal without increased
[18F]-PBR111 Vt. In the whole hippocampus, a signifi-
cant increase of 226% in [125I]-CLINDE binding was
found (Figure 6). When the subregions of the hippocam-
pus were analysed on the high-resolution autoradio-
graphic images, binding differences between the control
and KASE animals in CA1 (613%), CA2 (491%) and
CA3 (860%) were higher compared to the dorsal hippo-
campus as a whole (226%) (Figure 6). Other brain
regions analysed, i.e. the cortex, central thalamic nuclei,
hypothalamus, basolateral/medial amygdala and piriform
cortex showed significant increases in [125I]-CLINDE
binding compared to controls in agreement with the
OX-42 positive signal (Figure 6) and in vivo PET(Table 2). In corpus callosum, TSPO binding was not
significantly different from the control animals.
A correlation between Vt and r500 and autoradiography
binding was assessed for the hippocampus, thalamus
and amygdala. There was a discrepancy in the results for
one KASE rat, which did not show increased Vt, as men-
tioned above, but nevertheless had elevated r500 and
[125I]-CLINDE autoradiography binding (Figure 7). The
strongest correlation between in vivo measurements
Vt (excluding the [
18F]-PBR111-negative animal, Pearson
r = 0.76, P < 0.05) and r500 (Pearson r = 0.89, P < 0.01)
with autoradiography was found for the amygdala
(Figure 7). Highly significant correlations were found
between r500(SC) and Vt for the three brain regions
analysed (hippocampus: Pearson r = 0.87, P < 0.01;
thalamus: Pearson r = 0.96, P < 0.001 and amygdala:
Pearson r = 0.84, P < 0.01) after exclusion of the
[18F]-PBR111-negative animal (Figure 7).
Obvious cell loss was not present in any of the animals
in CA1, CA1 and CA3 regions, except for one KASE
animal, which displayed cell loss in CA4. Macroscopic
Figure 4 Time activity curves (TACs) of [18F]-PBR111. TACs were expressed as the percentage injected dose per milliliter (%ID/ml) of plasma
and several brain regions in the representative control (a) and KASE (severe SE) (b) rats. The increase in the amplitude of the cerebellum is
proportional to the plasma in both animals, while the increase in amygdala is much higher in the KASE compared to the control rat. Note that
the kinetics of the radioligand is also slower in the amygdala of the KASE animal.
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http://www.ejnmmires.com/content/2/1/60EB extravasation into the brain was not observed in the
subset of animals inspected.
Discussion
Brain inflammation was demonstrated and quantified
utilising both terminal histological/autoradiographicFigure 5 Evaluation of brain inflammation by the use of in vivo [18F]-
autoradiography and immunohistochemistry on the coronal sections in the
induction are shown. Arrows indicate the different brain regions named on
amygdala; PIR, piriform cortex.techniques as well as in vivo small animal PET imaging
7 days post-KA-induced SE. This study emphasised that
[18F]-PBR111, a specific TSPO binding radioligand, is a
promising radiotracer for imaging brain inflammation
during epileptogenesis. Particularly, TSPO overexpression
was observed after the induction of status epilepticus inPBR111 PET imaging (coronal plane). Corresponding post-mortem
representative control and KASE (severe SE) rats, 7 days post-SE
the ipsilateral hemisphere. HC, hippocampus; THAL, thalamus; AMYG,
AMYG
PIR
THAL
CA1
CA2
CA3
KASE
AMYG
PIR
THAL
CA1
CA2
CA3
CONTROL
Brain region (kBq/mg) Control (n=4) KASE (n=5) % increase OX42 +ve
Cortex 0.034  0.003 0.051  0.018 52% No/+
Corpus callosum (cc) 0.030  0.010 0.042  0.008 40% No
Hippocampus 0.047  0.022 0.153  0.009** 226% ++
Hippocampus (CA1) 0.024  0.008 0.169  0.031* 613% +++
Hippocampus (CA2) 0.029  0.007 0.172  0.039* 491% ++
Hippocampus (CA3)/hilus 0.025  0.010 0.238  0.038** 860% +++
Central thalamic nuclei (THAL) 0.078  0.020 0.318  0.031*** 309% ++
Hypothalamus (HYP) 0.033  0.007 0.056  0.004* 68% +
Basolateral/medial amygdala
(AMYG)
0.065  0.006 0.398  0.010*** 514% +++
Piriform cortex (PIR) 0.060  0.011 0.389  0.072* 545% +++
cc cc
Cortex Cortex
PYHPYH
Figure 6 [125I]-CLINDE autoradiography images and quantitative analyses. [125I]-CLINDE autoradiography images of the representative
control and KASE (severe SE) rats and quantitative analysis of [125I]-CLINDE specific binding (kBq/mg) in the control (N = 4) and KASE (N = 5)
groups of dorsal hippocampal sections are shown. Data were pooled for medium (N = 2) and severe SE (N = 3) groups as qualitative inspection
indicated that there was no difference in TSPO binding between the medium and severe groups. OX-42 + ve, OX-42 positive staining. Upward
arrow indicates increase; plus sign, mild; double plus sign, moderate; and triple plus sign, intense OX-42 signals. Data are expressed as
mean ± SEM; P < 0.05 (asterisk), P < 0.01 (double asterisk) and P < 0.001 (triple asterisk).
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ure generation and/or propagation. Interestingly, the se-
verity of the status epilepticus corresponded with the
extent of TSPO overexpression.
Recent animal studies have demonstrated that acutely
evoked seizures rapidly induce inflammatory mediators
in seizure prone brain regions (reviewed by [1]). Our
results are in line with the previous histological studies
which have demonstrated that the KASE model consti-
tutes an excellent model to study the involvement of
brain inflammation/translocator protein expression in
the genesis of epilepsy [14-16,28]. Because spatial infor-
mation is revealed by the techniques used in our study
(autoradiography of the brain sections and small animal
PET imaging), we were able to investigate the regional
pattern of increased TSPO expression. We have found
that the severity of the SE correlated well with the extent
of the brain inflammation, while a dose–response rela-
tionship between KA dose and TSPO expression was
not observed. These data suggest a direct relationship
between seizure activity and subsequent brain inflamma-
tion 1 week post-SE. More specifically, in animals thatdisplayed minor SE, significant TSPO overexpression
was not only considerably lower compared to the
medium SE group but also limited to the amygdala. Sev-
eral brain regions with high seizure susceptibility, such
as the hippocampus, amygdala and piriform cortex
showed significantly increased TSPO levels in animals
that underwent medium to severe SE, which is in line
with the previous reports [16,28]. Due to SE timing in
the animals and the differences in tissue sectioning and
analysis, it was not always possible to present the
complete imaging data for each SE state. Because in the
first group, brain sections were cut sagitally to have an
overview of the complete brain, we believe this data
cannot be directly compared against the first cohort of
animals, which was cut coronally to focus on the
hippocampus, thalamus and amygdala. Qualitatively,
based on the results of the PET study with two
medium and three severe animals, the data indicate
that there was no difference between TSPO binding/
inflammation between medium and severe groups.
Physiologically, this may be interpreted as follows:
once a certain degree of brain excitation/excitotoxicity
Table 2 Tissue distribution volumes of different VOIs
Brain region (Vt) Hemisphere Control (N = 4) KASE (N = 4) Increase (%)
Frontal cortex Left 5.4 ± 1.0 11.3 ± 2.4§ 108
Right 5.7 ± 1.2 11.2 ± 2.4§ 98
Striatum Left 2.8 ± 0.6 8.0 ± 1.2* 180
Right 3.0 ± 0.5 7.8 ± 1.1* 156
Parietal cortex Left 4.5 ± 0.6 9.5 ± 1.1§ 110
Right 4.9 ± 0.8 11.6 ± 2.0* 136
Hippocampus Left 3.6 ± 0.5 9.1 ± 1.1** 154
Right 3.6 ± 0.4 9.4 ± 1.6* 159
Thalamus Left 2.6 ± 0.5 7.0 ± 1.8§ 173
Right 2.8 ± 0.5 7.1 ± 1.4* 155
Hypothalamus 4.0 ± 0.7 8.2 ± 1.4§ 104
Amygdala Left 5.3 ± 0.8 20.6 ± 2.8** 288
Right 6.1 ± 0.7 23.4 ± 4.8* 284
Occipital cortex Left 9.8 ± 3.4 15.1 ± 3.5 53
Right 9.3 ± 1.4 15.0 ± 1.4* 62
Colliculi Left 4.0 ± 1.0 5.8 ± 1.1 44
Right 4.1 ± 1.1 6.9 ± 1.8 70
Brainstem 4.7 ± 0.8 6.7 ± 1.0 41
Pons 4.2 ± 0.9 7.5 ± 1.8 78
Cerebellum 7.5 ± 0.8 10.6 ± 1.3 43
Data are expressed as mean ± SEM; §P < 0.1, *P < 0.05 and **P < 0.01 compared to control.
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http://www.ejnmmires.com/content/2/1/60is reached, TSPO expression does not further increase.
However, more studies would be needed to confirm
this.
The results from the first in vitro experiment were
confirmed with in vivo [18F]-PBR111 PET imaging.
Interestingly, in addition to key regions for seizure gen-
eration in temporal lobe epilepsy, in vivo PET identified
several other brain regions with moderate levels of
increased TSPO binding such as the hypothalamus
(Table 1) which was in case of the hypothalamus con-
firmed by in vitro binding and immunohistochemistry in
the same animals (Table 2).
Only a limited number of animals (N = 4 to 5 per group)
were evaluated due to the complexity of this study as
small animal PET imaging with arterial input function in
this disease model requires the extensive coordination of a
great number of multi-disciplinary procedures namely the
induction of the model, tracer synthesis, animal prepar-
ation/anaesthesia, PET scanning, blood sample handling,
metabolite analysis, blood brain barrier integrity test, ani-
mal scarification and histology. The disadvantage of using
a relatively small sampling size is that changes in other
brain regions, e.g. the pons, that are less pronounced
could be missed due to type II errors.
Altar and Baudry [28] hypothesised that increased
TSPO expression in the post-KASE model was a result
of glial hypertrophy and proliferation in response to
cellular necrosis as TSPO increases were observed overa period of 1 to 2 weeks in regions prone to cell loss.
Our results indicate that TSPO expression could be a
more sensitive and early biomarker for epileptogenesis
than cell loss as substantial TSPO increases were not
accompanied by vast cell loss 1 week post-KASE. Indeed,
Vezzani and Friedman [29] suggested that inflammation
might be intrinsic to the epileptogenic process and there-
fore potentially an epileptogenesis biomarker.
Several studies utilising resected tissue from chronic
epileptic patients have shown increased TSPO binding
[5-7]. More recently, studies employing [11C]-PK11195,
although having inferior PET imaging characteristics
(signal-to-noise ratio) than [18F]-PBR111 [10], succeeded
in identifying focal and diffuse regions of activated
microglia in Rasmussen's encephalitis [30] and areas of
focal cortical dysplasia [31]. In temporal lobe epilepsy
patients, [11C]-PBR28, a recently developed carbon-11-
labelled TSPO ligand, showed increased binding ipsilat-
eral to the seizure focus [8]. This recent evidence and
our preclinical study implicate that TSPO imaging could
be a promising diagnostic biomarker: firstly, by helping
to identify the degree of inflammation and the affected
regions in patients and, therefore, TSPO PET imaging
could identify individuals that would benefit from anti-
inflammatory treatment; secondly, TSPO PET imaging
could act as a biomarker and possibly a surrogate mar-
ker for preclinical and clinical studies investigating
how drugs and potentially anti-inflammatory drugs
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Figure 7 In vivo and in vitro imaging correlations. (a) Correlation between in vivo ([18F]-PBR111 Vt and r500) and in vitro ([
125I]-CLINDE
autoradiography) measurements of TSPO binding for the hippocampus, thalamus and amygdala. (b) Correlation between [18F]-PBR111 Vt and r500
(SC) in vivo measurements of TSPO binding for the hippocampus, thalamus and amygdala. Circles indicate the Vt [
18F]-PBR111-negative animal,
with, in (a), open circles showing the Vt values for this animals and closed circles showing the r500(SC) value of this animal. This animal was
excluded for statistical correlation between Vt and ARG, and between Vt and r500(SC). ARG, autoradiography. Asterisk indicates P < 0.05; double
asterisk, P < 0.01; triple asterisk, P < 0.001; and section sign, P < 0.1.
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less, a better understanding of the inflammatory pro-
cesses will be needed before these applications become
clinical utilities. Preclinical TSPO small animal PET
imaging may play an important role in such validation
studies and increase our knowledge about the develop-
ment of brain inflammation during epileptogenesis and
its consequences.
However, there are several factors that may impede pre-
clinical and routine clinical TSPO imaging. Firstly, it has
been demonstrated that in some individuals, TSPO bind-
ing by several TSPO specific radioligands is negligible
[8,32]. This has been attributed to a low binding site, and
three subpopulations were identified: high affinity binders
(HAB), mixed affinity binders (MAB) and low affinity bin-
ders (LAB) [32]. Indeed, Owen et al. showed that TSPO
Ala147Thr polymorphism predicts PBR28 binding affinity
in human platelets [33]. Therefore, TSPO brain images
might not be conclusive for all individual epilepsy patients.
Even though [18F]-PBR111 affinity differences between
MAB and LAB are less pronounced than for TSPOligands such as [11C]-PBR28 and [11C]-PBR06 [32], also in
our study there was one KASE rat with conflicting data.
More specifically, while post-mortem microglia pathology
was observed, [18F]-PBR111 Vt was not increased. This
may relate to a higher dissociation constant (koff ) in ac-
cordance with the previously formulated existence of
HAB and LAB populations [32]. In vitro [125I]-CLINDE
autoradiography may be less susceptible to changes in koff
as autoradiography is generally performed at saturating
levels of radioligand concentration. Nevertheless, this does
not explain the discrepancy with the in vivo [18F]-PBR111
r500 data. Another explanation could be a difference in
tracer influx/efflux (k1/k2), a technical issue with the input
curve or a combination of both which is masking the
expected increase in Vt in this KASE animal. Possibly, a
late measurement is less susceptible for these alterations
than a kinetically modelled Vt, resulting in a divergence of
both in vivo measurements. Overall, r500 correlated well
with Vt and [
125I]-CLINDE autoradiography. This meas-
urement may provide a valuable non-invasive tool for
longitudinal studies.
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ruption of the blood brain barrier (BBB) during epilepto-
genesis and the chronic epileptic state [25,34], which
may cause tracer perfusion differences in the KASE
model and therefore differences in tracer influx (k1), as
well as tracer efflux (k2). Although, post-mortem verifica-
tion of EB extravasation in a subset of animals did not
reveal macroscopic disruption of the BBB at the time
of scanning in our study, this might be a potential
confounder. This question merits further investigation
for instance by using more complex experiments, such
as several injections of different masses of tracer to
identify all the parameters of the compartmental model
including the apparent affinity (KdVr) and density
(Bmax) [35,36]. We are planning such follow-up stud-
ies for [18F]-PBR111 in the control and KASE animals.
However, these types of protocols are invasive and
cumbersome and, therefore, not appropriate for longi-
tudinal follow-up.
Further, intrinsic factors to epilepsy such as partial
volume effects due to hippocampal sclerosis may result
in underestimation of TSPO expression in vivo. As the
inflammatory region may not exactly match the anatom-
ical structure, a pixel-wise partial volume correction
strategy merits consideration [37]. Indeed, autoradio-
graphic images clearly demonstrate that TSPO expres-
sion is not homogenous in the hippocampus with its
layered architecture. This may explain the lower correl-
ation of the in vivo measurements of the hippocampus
with autoradiography compared to the amygdala. Also in
the thalamus, TSPO expression was confined to specific
thalamic nuclei embracing the central part of the thal-
amus only. With VOI-based analysis, it is not possible to
extract this region from the MRI atlas, which may con-
tribute to the lower correlation between in vivo and
in vitro measurements of the thalamus. Statistical para-
metric mapping (SPM) with a voxel-wise comparison be-
tween the control and KASE groups based on a
simplified quantification output such as the r500 might
further improve the data. SPM on the other hand would
need to be conducted in sufficiently powered studies to
reach significant differences due to the need for correc-
tion of multiple comparisons.Conclusion
We have been able to demonstrate significant increases
in TSPO binding in brain regions relevant for epilepsy
employing both post-mortem autoradiography and
in vivo [18F]-PBR111 small animal PET imaging while
providing a non-invasive quantification method. This
study sets a much-needed translational framework for
studying brain inflammation and potentially for evaluat-
ing novel anti-inflammatory therapies using a PETimaging approach intended to facilitate the transfer of
knowledge from bench side to clinical application.
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